Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Document › Details

4SC AG. (3/6/13). "Press Release: 4SC AG. Dr Ulrich Dauer to Step Down as CEO and Member of the Management Board on 31 March 2013, His Successor Will Be CFO Enno Spillner". Planegg-Martinsried.

Organisations Organisation 4SC AG (FSE: VSC)
  Group 4SC (Group)
  Organisation 2 MC Services AG
Products Product small-molecule drug
  Product 2 cancer drug
Persons Person Dauer, Ulrich (Probiodrug 201805– CEO before Omeicos + Activaero + 4SC + Tripos)
  Person 2 Spillner, Enno (Evotec 201607– CFO before 4SC CEO + CFO before BioM Venture Capital GmbH)

4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that its Chief Executive Officer (CEO) and Chairman of the Management Board, Dr Ulrich Dauer, will be stepping down effective 31 March 2013 for personal reasons.

Dr Dauer, a founding member of 4SC and CEO of 4SC AG since 2000, is leaving the company by mutual agreement with the Supervisory Board and in a spirit of solidarity with the Management Board and will remain on amicable terms with the company.

The Supervisory Board of 4SC AG would like to thank Dr Dauer for his successful work over many years and his outstanding commitment to the company.

Enno Spillner, the company's CFO since 2005, has been appointed by the Supervisory Board as the CEO of 4SC AG with effect from 1 April 2013 and will hold both positions, CFO and CEO, in the future.

Dr Thomas Werner, Chairman of the Supervisory Board of 4SC AG, said: "Dr Dauer has made a great contribution to building up the company's reputation and establishing 4SC as one of Germany's most innovative biotechnology companies. We are sorry to lose him and would like to thank him for his successful work over many years and his outstanding commitment to the company. I wish him all the best for the future. Dr Dauer's departure on 31 March and the transfer of his position to Mr Spillner effective 1 April shall allow for an orderly handover as well as stable continuation of business within 4SC's Management Board."

Enno Spillner, CFO and designated CEO and Chairman of the Management Board of 4SC AG, said: "In the course of over 14 years at 4SC, Ulrich Dauer was instrumental in shaping the company into what it is today. On behalf of the Management Board of 4SC AG and the entire company, I would like to thank him for his great contributions to the company and for his dedicated and constructive collaboration as a friend of our company."


About 4SC

The Group managed by 4SC AG (ISIN DE0005753818) discovers and develops targeted, small-molecule drugs for treating diseases with high unmet medical needs in various autoimmune and cancer indications. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The Company's balanced pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with leading pharmaceutical companies. Founded in 1997, 4SC had 86 employees at the end of 2012. 4SC AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.

Legal Note

This document may contain projections or estimates relating to plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements; each of which constitutes a forward-looking statement subject to risks and uncertainties, many of which are beyond our control. Actual results could differ materially, depending on a number of factors.

For more information please visit or contact:

Jochen Orlowski, Corporate Communications & Investor Relations
jochen.orlowski(at), Tel.: +49-89-7007-63-66

MC Services
Mareike Mohr, Raimund Gabriel
mareike.mohr(at) , Tel.: +49-89-2102-28-40
raimund.gabriel(at) , Tel.: +49-89-2102-28-30

The Trout Group
Chad Rubin
Crubin(at), Tel.: +1-646-378-2947

Record changed: 2017-04-02


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for 4SC (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

» top